The stock of ValiRx Plc (LON:VAL) is a huge mover today! The stock increased 1.23% or GBX 0.08 on November 22, hitting GBX 6.58. About 816,007 shares traded hands or 4.22% up from the average. ValiRx Plc (LON:VAL) has declined 24.64% since April 22, 2016 and is downtrending. It has underperformed by 29.19% the S&P500.
The move comes after 6 months negative chart setup for the GBX 5.69 million company. It was reported on Nov, 22 by Barchart.com. We have GBX 5.99 PT which if reached, will make LON:VAL worth GBX 512,100 less.
ValiRx Plc (LON:VAL) Ratings Coverage
Out of 2 analysts covering ValiRx PLC (LON:VAL), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. ValiRx PLC has been the topic of 23 analyst reports since September 16, 2015 according to StockzIntelligence Inc. On Thursday, August 11 the stock rating was maintained by Northland Capital with “Corporate”. The firm earned “Speculative Buy” rating on Tuesday, June 7 by Beaufort Securities. The stock has “Corporate” rating given by Northland Capital on Friday, April 29. The firm has “Corporate” rating given on Thursday, November 3 by Northland Capital. On Wednesday, September 16 the stock rating was maintained by Northland Capital with “Corporate”. The stock of ValiRx Plc (LON:VAL) earned “Speculative Buy” rating by Beaufort Securities on Wednesday, October 26. Northland Capital maintained the stock with “Corporate” rating in Thursday, July 28 report. The rating was maintained by Northland Capital with “Corporate” on Thursday, October 13. The firm has “Corporate” rating given on Friday, November 20 by Northland Capital. The stock of ValiRx Plc (LON:VAL) earned “Corporate” rating by Northland Capital on Tuesday, September 27.
Another recent and important ValiRx Plc (LON:VAL) news was published by Uk.Finance.Yahoo.com which published an article titled: “-LSE Ticker: WWYSP4/ISIN: GB00BWWYSP41” on March 17, 2014.
ValiRx plc is a biopharmaceutical company. The company has a market cap of 5.69 million GBP. The principal activity of the Company is the development of oncology therapeutics and companion diagnostics. It currently has negative earnings. It focuses on the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.